1 April 2016 - The fixed-dose combination of the drugs elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide has been available under the trade name Genvoya since November 2015 as treatment for adults and adolescents aged over 12 years infected with human immunodeficiency virus type 1 (HIV-1). The German IQWiG has examined in an early benefit assessment whether this new combination product offers an added benefit for patients with HIV-1 infection in comparison with the appropriate comparator therapy.

According to the findings, there is a hint of a minor added benefit for pretreated women without indication for a treatment switch, but not for men. Negative effects predominate in treatment-naive adults, irrespective of gender. Hence here IQWiG sees a hint of lesser benefit in comparison with the comparator therapy. There were no data for adolescents.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/genvoya-in-hiv-positive-effects-predominate-in-some-adults-negative-effects-in-others.7233.html

To see these entries for Genvoya in the MAESTrO database, go to: https://app.maestrodatabase.com/app/reimbursement/browse/technology/emtricitabine-with-elvitegravir-and-cobicistat-and-tenofovir-alafenamide?agency=iqwig [Paid subscribers only]